Cancer Institute New South Wales (CINSW), St Leonards, New South Wales, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Asia Pac J Clin Oncol. 2024 Aug;20(4):491-496. doi: 10.1111/ajco.14067. Epub 2024 Apr 17.
To understand the current usage of eviQ Cancer Treatments Online (www.eviQ.org.au), an Australian, open-access website providing evidence-based and consensus-driven cancer treatment protocols and information, and the extent to which it is meeting its intended outcomes and providing value to its users.
A mixed-method evaluation was conducted in 2020-2022 which included a review of key program documentation and website usage data, and delivery of a focused online survey to its users.
In 2022, 329 clinicians representing all Australian states and territories contributed to eviQ content development and review. eviQ content continues to grow with a 15.2% increase in total content from 2019 to 2022. eviQ website users continue to grow with 90,000 total monthly users in 2022, representing a 166% increase from 2018. The proportion of international users compared to Australian users continues to grow with 57% of total users in Australia and 43% international in 2022. Of 466 survey responses, the most cited reason for eviQ use was for information on side effects/toxicity (67%). Ninety-three percent (93%) of respondents either agreed or strongly agreed that eviQ contributed to both health professionals providing the best evidence-based treatment and care and improving the standardization of treatment and care provided.
eviQ is embedded in Australian clinical practice, highly valued, and relied upon by users. Users agree that eviQ has a positive impact on patients by supporting the delivery of evidence-based treatment and that eviQ contributed to patients' improved health outcomes and quality of life. eviQ's increasing international usage should be explored.
了解澳大利亚开放获取网站 eviQ Cancer Treatments Online（www.eviQ.org.au）的使用情况，该网站提供基于证据和共识的癌症治疗方案和信息，评估其是否达到预期目标并为用户提供价值。
2020 年至 2022 年进行了混合方法评估，包括审查关键项目文件和网站使用数据，并向用户提供重点在线调查。
2022 年，代表澳大利亚所有州和地区的 329 名临床医生参与了 eviQ 内容的开发和审查。eviQ 内容不断增长，2019 年至 2022 年总内容增加了 15.2%。eviQ 网站用户持续增长，2022 年总用户数达到 9 万，比 2018 年增长了 166%。国际用户与澳大利亚用户的比例继续增长，2022 年澳大利亚用户占 57%，国际用户占 43%。在 466 份调查回复中，使用 eviQ 的最主要原因是获取副作用/毒性信息（67%）。93%的受访者表示同意或强烈同意 eviQ 有助于医疗保健专业人员提供最佳基于证据的治疗和护理，并提高治疗和护理的标准化。
eviQ 已融入澳大利亚临床实践，深受用户重视和信赖。用户认为 eviQ 通过支持提供基于证据的治疗对患者产生了积极影响，并且 eviQ 有助于改善患者的健康结果和生活质量。应进一步探索 eviQ 的国际使用情况。
